CF pancreatic treatment gets Medicare preferred status

Beneficiaries to see lower costs for enzyme replacement therapy Pancreaze

Written by Marisa Horak, MS |

An image of a human body highlights the pancreas.

Pancreaze provides purified versions of pancreatic enzymes to help improve digestion. (Photo by iStock)

Pancreaze (pancrelipase), an approved therapy used to manage pancreatic complications in cystic fibrosis (CF), has been added as a preferred therapy on a National Medicare Part D formulary, according to the therapy’s maker, Vivus.

The move means lower out-of-pocket costs for patients receiving the medication through Medicare, the government-funded program that provides health insurance to people 65 and older and certain people with disabilities in the U.S.

Part D is the portion of Medicare that covers prescription drugs. According to Vivus, this program covers approximately 8.8 million people nationwide. The new status is effective Jan. 1, 2027.

“This addition of PANCREAZE to a National Medicare Part D preferred formulary underscores the strong clinical value our treatment brings to patients and healthcare providers,” Santosh T. Varghese, MD, president of global pharmaceutical development and chief medical officer of Vivus, said in a company press release. “This expanded coverage is a meaningful milestone that helps reduce treatment barriers.”

Recommended Reading
Banner image for Jennifer Cogliano's Living Beyond column on cystic fibrosis issues.

The ending of my Medicare prescription drug plan has left me scrambling

Replacing enzymes

CF is a genetic disorder characterized by abnormally thick and sticky mucus, which builds up in organs to drive CF symptoms. The pancreas is one of the organs usually heavily affected by CF.

Normally, the pancreas is responsible for making digestive enzymes, which it then ships out to the intestines through a series of ducts and tubes. But in CF, thick mucus can clog the transportation system, preventing pancreatic enzymes from getting into the intestines. This is called exocrine pancreatic insufficiency (EPI), and it makes it harder for patients to adequately absorb nutrients from the food they eat.

Pancreaze is a form of pancreatic enzyme replacement therapy (PERT), a standard EPI treatment in which purified versions of pancreatic enzymes are taken orally to help improve digestion. Pancreaze uses a cocktail of enzymes derived from pig pancreases. Vivus noted that its formulation does not use phthalates, chemicals often used in plastics as well as medication coatings.

“Ensuring that Medicare beneficiaries living with exocrine pancreatic insufficiency have reliable, cost-effective access to essential enzyme replacement therapy is a top priority for VIVUS,” said John Amos, CEO of Vivus. “The decision to grant PANCREAZE preferred status on a National Medicare Part D formulary provides millions of patients and their healthcare providers an affordable, high-quality option with a flexible, phthalate-free PERT formulation.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.